Subsequently, nab-paclitaxel was infused, and after completion, the erythematous macules on the limbs faded
Confirmatory secondary endpoints included 20%, 25%, and 30% weight loss, with all analyses performed on an intention-to-treat basis and reported with 95% confidence intervals
Clearly labeled vials with volume, formulation, and Research Use Only printed for quick verification
Richard Frank, MD, MHSA, Chief Medical Officer at Vida Health, spoke to Medical News Today about how orforglipron may expand access to GLP-1s: The choice between a pill and an injectable comes down to patient preference and potency. The injectables are clearly more potent but require a weekly injection